Acute Infection and Myocardial Infarction

Frank, R; Hanidziar, Dusan

doi:10.1056/nejmc1901647

Cited by 11 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[54][55][56] Despite the unknown etiology of ACS in COVID-19 patients, several pathways in virus-induced diseases have been indicated, which may instigate plaque instability and account for some of these cases. [57] The mechanisms underlying COVID-19-induced plaque instability may also involve systemic inflammatory responses such as the cytokine storm. [58] SARS-CoV-2 has been shown to replicate and proliferate in several types of endothelial cells, leading to cellular swelling and apoptosis, and ultimately endothelial dysfunction.…”

Section: Covid-19 Causes Acute Crisis Of Heart: Coronary Syndrome And...mentioning

confidence: 99%

COVID-19 and cardiovascular complications: updates of emergency medicine

Zhao

Xie²,

Meng³

et al. 2023

Emerg Crit Care Med

View full text Add to dashboard Cite

Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV-2 variants, has become a global pandemic resulting in significant morbidity and mortality. Severe cases of COVID-19 are characterized by hypoxemia, hyperinflammation, cytokine storm in lung. Clinical studies have reported an association between COVID-19 and cardiovascular disease (CVD). Patients with CVD tend to develop severe symptoms and mortality if contracted COVID-19 with further elevations of cardiac injury biomarkers. Furthermore, COVID-19 itself can induce and promoted CVD development, including myocarditis, arrhythmia, acute coronary syndrome, cardiogenic shock, and venous thromboembolism. Although the direct etiology of SARS-CoV-2-induced cardiac injury remains unknown and underinvestigated, it is suspected that it is related to myocarditis, cytokine-mediated injury, microvascular injury, and stress-related cardiomyopathy. Despite vaccinations having provided the most effective approach to reducing mortality overall, an adapted treatment paradigm and regular monitoring of cardiac injury biomarkers is critical for improving outcomes in vulnerable populations at risk for severe COVID-19. In this review, we focus on the latest progress in clinic and research on the cardiovascular complications of COVID-19 and provide a perspective of treating cardiac complications deriving from COVID-19 in emergency medicine.

show abstract

Section: Covid-19 Causes Acute Crisis Of Heart: Coronary Syndrome And...mentioning

confidence: 99%

COVID-19 and cardiovascular complications: updates of emergency medicine

Zhao

Xie²,

Meng³

et al. 2023

Emerg Crit Care Med

View full text Add to dashboard Cite

show abstract

“…The likelihood of MI in respiratory infectious diseases outstretches the apex at the outset of the illness and is pro-rata to the intensity of the infection 29 . A primary coronary artery event such as Type 1 MI attributing to acute plaque rupture and events occurring secondary to an acute imbalance in myocardial oxygen supply and demand such as Type 2 MI can ensue in COVID-19 infection, 5,7 as Type 2 MI manifests similar to COVID-19 symptoms such as dyspnoea, chest pain etc., it is challenging to identify/diagnose the same and patients may present with a high prevalence of comorbidities which may obscure ischemia and localized wall abnormalities which are mysterious 30 .…”

Section: Acute Coronary Syndrome (Acs)-nstemi and Stemimentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

, caused by Severe Acute Respiratory Syndrome CoV-2 (SARS CoV-2), has become a global burden. The naïve era of infection prompted early dependence on case reports of insufficient data and conceptual elucidation to explain and anticipate the effect on cardiovascular diseases. Many COVID-19-infected and vaccinated individuals have reported an increased incidence of cardiovascular disorders, leading to higher morbidity and mortality rates. Sometimes COVID can also manifest as a severe coronary artery disease or myocarditis in those with no background in cardiovascular diseases or those with cardiovascular risk factors, which are often misunderstood as a primary cardiovascular disorder. COVID-induced cardiovascular complications like DVT, VTE, MI, and long COVID have been the crux of the matter. To combat the SARS-CoV-2 disease, several countries took the lead in developing COVID-19 vaccines, but only a few were effective against coronavirus, which created a ray of hope in curbing COVID-19 disease. As the thumb rule says, any substance that is foreign to the body, including vaccines, has flaws seen in the forms of adverse effects/adverse events, which has created a great reluctance towards accepting COVID vaccine in society. Despite all this, it is proven that vaccines are effective in managing the COVID-19 situation worldwide, underlining the Darwinian notion.INTRODUCTION: COVID-19, caused by Severe Acute Respiratory Syndrome CoV-2 (SARS CoV-2), has become a global burden infecting more than 41 million individuals by the end of January 2022 in India 1 . The outbreak of this disease was in Wuhan, China, in December 2019 and was transmitted impulsively throughout the Globe. Since then, researchers have faced a network of provocations with tackling the disease 2 .

show abstract

“…Potential mechanisms of cardiovascular injury in COVID-19 include hemodynamic derangement or hypoxemia, increased metabolic stress, demand ischemia, microvascular dysfunction or thrombosis due to hypercoagulability, or systemic inflammation and cytokine storm, which may also destabilize existing coronary artery plaques (16,(74)(75)(76).…”

Section: Pathophysiology Of Covid-19 and Cardio-oncologymentioning

confidence: 99%

Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology

Brown

Zaharova

Mason

et al. 2020

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Overlapping commonalities between coronavirus disease of 2019 (COVID-19) and cardio-oncology regarding cardiovascular toxicities (CVT), pathophysiology, and pharmacology are special topics emerging during the pandemic. In this perspective, we consider an array of CVT common to both COVID-19 and cardio-oncology, including cardiomyopathy, ischemia, conduction abnormalities, myopericarditis, and right ventricular (RV) failure. We also emphasize the higher risk of severe COVID-19 illness in patients with cardiovascular disease (CVD) or its risk factors or cancer. We explore commonalities in the underlying pathophysiology observed in COVID-19 and cardio-oncology, including inflammation, cytokine release, the renin-angiotensin-aldosterone-system, coagulopathy, microthrombosis, and endothelial dysfunction. In addition, we examine common pharmacologic management strategies that have been elucidated for CVT from COVID-19 and various cancer therapies. The use of corticosteroids, as well as antibodies and inhibitors of various molecules mediating inflammation and cytokine release syndrome, are discussed. The impact of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is also addressed, since these drugs are used in cardio-oncology and have received considerable attention during the COVID-19 pandemic, since the culprit virus enters human cells via the angiotensin converting enzyme 2 (ACE2) receptor. There are therefore several areas of overlap, similarity, and interaction in the toxicity, pathophysiology, and pharmacology profiles in COVID-19 and cardio-oncology syndromes. Learning more about either will likely provide some level of insight into both. We discuss each of these topics in this viewpoint, as well as what we foresee as evolving future directions to consider in cardio-oncology during the pandemic and beyond. Finally, we highlight commonalities in health disparities in COVID-19 and cardio-oncology and encourage continued development and implementation of innovative solutions to improve equity in health and healing.

show abstract

Acute Infection and Myocardial Infarction

Cited by 11 publications

References 7 publications

COVID-19 and cardiovascular complications: updates of emergency medicine

COVID-19 and cardiovascular complications: updates of emergency medicine

Untitled

Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology

Contact Info

Product

Resources

About